Study Evaluating Prevenar in High-Risk Children - Full Text View

Study Evaluating Prevenar in High-Risk Children

This study has been completed.

Sponsored by:	Wyeth
Information provided by:	Wyeth
ClinicalTrials.gov Identifier:	NCT00234338

Purpose

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.

Condition

Pneumococcal Disease

ChemIDplus related topics:

Heptavalent pneumococcal conjugate vaccine Pneumococcal Vaccines

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective

Official Title:	Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years

Further study details as provided by Wyeth:

Eligibility

Criteria

Inclusion Criteria:

Exclusion criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00234338

Locations

Sponsors and Collaborators

Wyeth

Investigators


Study Director:	Medical Monitor	Wyeth

Principal Investigator:	Trial Manager	For Germany, MedInfoDEU@wyeth.com

More Information

Study ID Numbers:	101850
First Received:	October 4, 2005
Last Updated:	December 7, 2007
ClinicalTrials.gov Identifier:	NCT00234338
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Wyeth:

Children

Vaccine

Prevenar

ClinicalTrials.gov processed this record on October 17, 2008